| 31 Janvier 2018
29 JANUARY 2018 | BANGKOK - WHO’s first release of  surveillance data on antibiotic resistance reveals high levels of  resistance to a number of serious bacterial infections in both high- and  low-income countries.
WHO’s new Global Antimicrobial Surveillance System (GLASS) reveals  widespread occurrence of antibiotic resistance among 500 000 people with  suspected bacterial infections across 22 countries.
 
 The most commonly reported resistant bacteria were Escherichia coli,  Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus  pneumoniae, followed by Salmonella spp. The system does not include data  on resistance of Mycobacterium tuberculosis, which causes tuberculosis  (TB), as WHO has been tracking it since 1994 and providing annual  updates in the Global tuberculosis report.
 
 Among patients with suspected bloodstream infection, the proportion that  had bacteria resistant to at least one of the most commonly used  antibiotics ranged tremendously between different countries – from zero  to 82%. Resistance to penicillin – the medicine used for decades  worldwide to treat pneumonia – ranged from zero to 51% among reporting  countries. And between 8% to 65% of E. coli associated with urinary  tract infections presented resistance to ciprofloxacin, an antibiotic  commonly used to treat this condition.
 
 “The report confirms the serious situation of antibiotic resistance  worldwide,” says Dr Marc Sprenger, director of WHO’s Antimicrobial  Resistance Secretariat.
 
 “Some of the world’s most common – and potentially most dangerous –  infections are proving drug-resistant,” adds Sprenger. “And most  worrying of all, pathogens don’t respect national borders. That’s why  WHO is encouraging all countries to set up good surveillance systems for  detecting drug resistance that can provide data to this global system.”
 
 To date, 52 countries (25 high-income, 20 middle-income and 7 low-income  countries) are enrolled in WHO’s Global Antimicrobial Surveillance  System. For the first report, 40 countries provided information about  their national surveillance systems and 22 countries also provided data  on levels of antibiotic resistance.
 
 “The report is a vital first step towards improving our understanding of  the extent of antimicrobial resistance. Surveillance is in its infancy,  but it is vital to develop it if we are to anticipate and tackle one of  the biggest threats to global public health,” says Dr Carmem  Pessoa-Silva, who coordinates the new surveillance system at WHO.
 
 Data presented in this first GLASS report vary widely in quality and  completeness. Some countries face major challenges in building their  national surveillance systems, including a lack of personnel, funds and  infrastructure.
 
 However, WHO is supporting more countries to set up national  antimicrobial resistance surveillance systems that can produce reliable,  meaningful data. GLASS is helping to standardize the way that countries  collect data and enable a more complete picture about antimicrobial  resistance patterns and trends.
 
 Solid drug resistance surveillance programmes in TB, HIV and malaria  have been functioning for many years and have helped estimate disease  burden, plan diagnostic and treatment services, monitor the  effectiveness of control interventions, and design effective treatment  regimens to address and prevent future resistance. GLASS is expected to  perform a similar function for common bacterial pathogens.
 
 The rollout of GLASS is already making a difference in many countries.  For example, Kenya has enhanced the development of its national  antimicrobial resistance system; Tunisia started to aggregate data on  antimicrobial resistance at national level; the Republic of Korea  completely revised its national surveillance system to align with the  GLASS methodology, providing data of very high quality and completeness;  and countries such as Afghanistan or Cambodia that face major  structural challenges have enrolled in the system and are using the  GLASS framework as an opportunity for strengthening their AMR  surveillance capacities. In general, national participation in GLASS is  seen as a sign of growing political commitment to support global efforts  to control antimicrobial resistance.
http://www.who.int/mediacentre/news/releases/2018/antibiotic-resistance-found/en/









